Hormonal Management and Structural Changes in Climacteric

Genitourinary Syndrome of Menopause (GSM)

The transition toward the permanent cessation of ovarian function triggers severe structural changes that modern medicine classifies under the diagnosis of Genitourinary Syndrome of Menopause (GSM), replacing the obsolete and incomplete term “vaginal atrophy.”

The permanent decline in estrogen and testosterone levels causes the vulvovaginal epithelium to lose collagen, becoming extremely thin, pale, and fragile, and losing its natural elastic folds.

Clinically, this tissue atrophy manifests as chronic irritation, intense burning, microtears during penetration, and a drastic increase in internal pH, which facilitates recurrent infections.

Furthermore, the hormonal deficit directly affects the lower urinary tract, causing urinary urgency, incontinence, and a predisposition to cystitis.

Recognizing SGM as a chronic and progressive condition that does not resolve spontaneously is the first vital step toward seeking medical intervention, preventing pain from obliterating the physiological capacity to experience pleasure in later life.

Hormone Replacement Therapy (HRT) and Its Clinical Impact

Hormone Replacement Therapy (HRT) is the most effective first-line intervention for reversing the anatomical changes associated with menopause, despite the myths and unfounded fears that have historically limited its prescription.

Systemic administration (orally or transdermally via patches or gels) restores overall endocrine balance, preserving bone density and improving cardiovascular and neurological well-being.

To specifically treat Genitourinary Syndrome, topical or local HRT (estrogen ovules, creams, or rings) is exceptionally safe, as it acts directly on receptors in the pelvic tissue without reaching the bloodstream in significant doses.

This localized approach regenerates mucosal thickness, restores elasticity, normalizes the protective acidic pH, and revitalizes the clitoral nerve networks, eliminating friction-related pain (dyspareunia) and restoring the structural integrity necessary to maintain an active, comfortable, and fully satisfying intimate life.

Vasomotor symptoms, insomnia, and the neurological sexual brake

Perimenopausal endocrine fluctuations trigger systemic symptoms that act as powerful neurological inhibitors of sexual desire.

Vasomotor symptoms, commonly known as hot flashes and night sweats, cause severe disruptions in thermoregulation and continuously fragment sleep architecture.

The resulting chronic insomnia depletes energy reserves, raising cortisol levels and plunging the brain into a state of survival and constant alertness.

In this context of systemic exhaustion, the sexual inhibition system (the neurological “brake”) is automatically activated, suppressing any intimate impulse by deeming it biologically unfeasible.